Prestige Wealth Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $60K | Sell |
184
-132
| -42% | -$43K | 0.01% | 237 |
|
|
2025
Q1 | $85.3K | Hold |
316
| – | – | 0.02% | 207 |
|
|
2024
Q4 | $74.4K | Sell |
316
-135
| -30% | -$31.8K | 0.02% | 221 |
|
|
2024
Q3 | $124K | Buy |
451
+179
| +66% | +$49.2K | 0.03% | 178 |
|
|
2024
Q2 | $66.1K | Sell |
272
-200
| -42% | -$48.6K | 0.01% | 206 |
|
|
2024
Q1 | $70.5K | Buy |
472
+194
| +70% | +$29K | 0.02% | 229 |
|
|
2023
Q4 | $53.2K | Sell |
278
-36
| -11% | -$6.89K | 0.01% | 238 |
|
|
2023
Q3 | $55.6K | Buy |
314
+304
| +3,040% | +$53.8K | 0.01% | 232 |
|
|
2023
Q2 | $1.9K | Hold |
10
| – | – | ﹤0.01% | 768 |
|
|
2023
Q1 | $2K | Buy |
10
+3
| +43% | +$601 | ﹤0.01% | 742 |
|
|
2022
Q4 | $1.66K | Sell |
7
-30
| -81% | -$7.13K | ﹤0.01% | 868 |
|
|
2022
Q3 | $7K | Sell |
37
-1,480
| -98% | -$280K | ﹤0.01% | 473 |
|
|
2022
Q2 | $221K | Buy |
1,517
+293
| +24% | +$42.7K | 0.06% | 127 |
|
|
2022
Q1 | $200K | Buy |
1,224
+600
| +96% | +$98K | 0.05% | 141 |
|
|
2021
Q4 | $105K | Buy |
624
+580
| +1,318% | +$97.6K | 0.03% | 192 |
|
|
2021
Q3 | $9K | Buy |
44
+14
| +47% | +$2.86K | ﹤0.01% | 496 |
|
|
2021
Q2 | $5K | Hold |
30
| – | – | ﹤0.01% | 607 |
|
|
2021
Q1 | $4K | Hold |
30
| – | – | ﹤0.01% | 647 |
|
|
2020
Q4 | $4K | Hold |
30
| – | – | ﹤0.01% | 611 |
|
|
2020
Q3 | $4K | Hold |
30
| – | – | ﹤0.01% | 555 |
|
|
2020
Q2 | $4K | Hold |
30
| – | – | ﹤0.01% | 541 |
|
|
2020
Q1 | $3K | Buy |
+30
| New | +$3K | ﹤0.01% | 556 |
|